New machine-learning tech 'reads and interprets data like a PhD scientist'
Scientists can now dramatically reduce trial-and-error experimentation and uncover risks early thanks to an artificial intelligence solutions company.
Scientists can now dramatically reduce trial-and-error experimentation and uncover risks early thanks to an artificial intelligence solutions company.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.